The purpose of our study was to examine the effect of intravenous (IV) 
Nicardipine reduces the cardio-respiratory toxicity of intravenously administered bupivacaine in rats Calcium channel antagonists are frequently used in the treatment of angina pectoris, hypertension, and cardiac dysrhythmias, both chronically and acutely in the perioperative period. Other investigators have previously shown that bupivacaine inhibits both fast sodium-dependent channels and slow calcium-dependent channels.
3 ' 4 Many patients undergoing surgery with bupivacaine regional anaesthesia will already be taking calcium channel entry blockers, and/or will receive them perioperatively, and thus there is considerable potential for drug interactions CAN J ANAESTH 1990 / 37: 8 / pp 920-3 between these drugs. Drug interactions are probably more common than is usually appreciated, and may be either harmful to the patient, especially if not recognized early, or beneficial, if they can be utilized to increase a desired effect. 5 In the presence of calcium channel blockers, bupivacaine may be more cardiotoxic, 6 although this issue is unsettled, as other studies suggest that some calcium channel blockers may reduce bupivacaine cardiotoxicity. 7 Nicardipine, a new dihydropyridine calcium channel antagonist structurally related to nifedipine, has been shown to reduce systemic vascular resistance and to produce potent coronary vasodilatation without negative inotropic effect. 8 We have previously shown that pretreatment with verapamil protects against the cardiorespiratory toxicity due to bolus IV bupivacaine in adult male Sprague Dawley rats. 7 The purpose of the present study was to investigate the effect of nicardipine pretreatment on bupivacaine's cardio-respiratory toxicity.
Methods
Our Institution's Animal Care Committee guidelines were followed throughout the study. The protocol was essentially identical to that which we have previously reported. 7 Fifty adult male Sprague Dawley rats weighing approximately 300 g were randomly divided into four groups and anaesthetized with intraperitoneal pentobarbital 40 mg • kg"' (initial dose) until they were unresponsive to a painful stimulus (pinching skin with a forceps). Lead II of the ECG was monitored with a Hewlett-Packard monitor, precordial pulsations were observed through an illuminated magnifying lens, and respiratory rate was monitored. Aftercutdown, a femoral vein wascannulated with a 24-gauge IV catheter, and 20 (xl was taken for blood gas analysis in a Corning 168 analyzer. Saline, 0.5 ml IV, was given after venous blood sampling.
Our preliminary dose response experiments in Sprague Dawley rats had shown that 5 mg-kg" 1 , 0.5 per cent bupivacaine was fatal in about 90 per cent of the rats (LD 90 ), and that 3.5 mg • kg"' was fatal in fewer than ten TABLE I Baseline data* per cent. Based on these preliminary results with 0.5 per cent bupivacaine, 3.5 mg-kg" 1 and 5 mg-kg" 1 were chosen as the doses for the study of cardio-respiratory toxicity.
Groups I and II received 3.5 mg-kg" 1 , 0.5 per cent bupivacaine IV, and Groups III and IV received 5 mgkg" 1 . Groups I and III were given pretreatment with normal saline (NS) placebo IV (a volume equal to the volume of nicardipine they would have received had they been in a nicardipine group), whereas Groups II and IV were given pretreatment with nicardipine 30 (xg • kg"' (50 |xg-ml"' in NS), a dose that has been recommended for human patients. 8 Pretreatment was given slowly over two minutes. One minute following completion of pretreatment, i.e., three minutes after beginning pretreatment, all rats were given either 3.5 mg-kg" 1 (Groups I and II) or 5 mg • kg"' (Groups III and IV), 0.5 per cent bupivacaine as a rapid IV bolus injection (in ^2 sec). Studies were performed between 9 a.m. and 12 noon. Rats were neither ventilated nor oxygenated, in order to simulate a frequent clinical scenario at the onset of bupivacaine cardio-respiratory toxicity, namely that the patient is apnoeic.
Five minutes after bupivacaine injection, rats were classified as fatalities or survivors. 7 Rats that maintained adequate respiration and heart rate and did not develop cyanosis were classified as survivors. Rats that developed apnoea, cyanosis and ultimately, agonal rhythm or asystole, were classified as fatalities.
Data on body weights, pentobarbital doses, and blood gas analyses were compared using analysis of variance (ANOVA). Incidences of survival and fatality were compared using Chi-square analysis with Yates' correction. P values <0.05 were considered statistically significant.
Results
There were no differences in the body weights, pentobarbital doses or blood gas results among the four groups (ANOVA) (see Baseline Data, Table I •The mean (±SEM) baseline venous blood gas tensions, weights and pentobarbital doses are shown. P > 0.05 for all groups (ANOVA). Table II . All rats receiving low-dose bupivacaine (Groups I and II) survived (ten often in both groups). For the rats given high-dose bupivacaine, 5 mg-kg" 1 , there was a statistically significant greater survival in the group receiving nicardipine pretreatment (13 of 15 in Group IV, 87 per cent), compared with rats receiving NS placebo (four of 15 in Group 111,27 per cent) (P < 0.001).
Rats given low-dose bupivacaine had no significant changes in respiration or cardiac rhythm; two such rats had transient, spontaneously resolving apnoea (<5 sec). All rats given high-dose bupivacaine became apnoeic approximately eight to 14 seconds after bupivacaine injection, followed shortly afterwards (within 2-5 sec) by the onset of cardiac arrhythmias. Typically, these consisted of fleeting sinus tachycardia, which ushered in brief second or third degree atrioventricular block, followed either by reversion to sinus tachycardia with resumption of adequate respirations (in the survivors), or progression to (brief) complete heart block and then, promptly, asystole, associated with persistent apnoea (in the fatalities). Surviving rats spontaneously resumed respiration within about ten seconds, never developed cyanosis, and continuously maintained precordial pulsations. On the contrary, fatalities became deeply cyanotic, never resumed respiration, lost precordial pulsations, and developed slow agonal rhythms and/or asystole within 40-45 sec of receiving bupivacaine.
Discussion
When bupivacaine is given intravascularly, it probably causes the most cardio-respiratory toxicity of all local anaesthetics. Because of this the US Food and Drug Administration withdrew the 0.75 per cent concentration of bupivacaine from use in obstetrical anaesthesia in 1984. 9 However, bupivacaine is still used extensively for epidural anaesthesia because of its unique, superior properties of long duration of action, high potency, and relatively less motor blockade for a given degree of sensory block. 10 The mechanism of bupivacaine cardio-respiratory toxicity is not clear, nor does the present study establish the mechanism. Clerkson" explained the mechanism of bupivacaine cardiotoxicity with the modulated receptor hypothesis put forward by Hille, 12 proposing that bupivacaine blocks cardiac sodium channels in a time-and voltage-dependent fashion. Relative to sodium, bupivacaine has an enhanced affinity for inactive myocardial sodium channels, thereby reducing sodium conductance and blocking the maximum upstroke velocity of the myocardial action potential (V max ). Furthermore, diastolic recovery from channel blockade is relatively slow for bupivacaine, compared with lidocaine. With respect to their properties relative to myocardial sodium channels, lidocaine is a "fast-in, fast-out" drug, whereas bupivacaine is a "fast-in, slow-out" drug. Thus, bupivacaine is felt to display prolonged cardiotoxicity clinically, including pronounced atrioventricular conduction disturbances and ventricular arrhythmias, because of the long time constant for its myocardial sodium channel blockade.
At high blood concentrations, bupivacaine is known to increase systemic and pulmonary vascular resistance in dogs 13 and sheep, M l 5 and it has also been speculated that it may cause coronary vasoconstriction in guinea pigs, 16 or reduced coronary perfusion without coronary vasoconstriction. l 6 Nicardipine is a potent coronary and systemic arterial vasodilator that lacks a pronounced inotropic effect. 8 The dose of nicardipine used, 30 jxg-kg" 1 IV, is enough to dilate coronary arteries. Since bupivacaine increases systemic and pulmonary vascular resistance, and may cause coronary vasoconstriction as well, perhaps nicardipine's potent vasodilatory properties explain its protective effect against bupivacaine cardio-respiratory toxicity. Calcium channel entry blocking drugs are also known to possess sodium channel blocking properties when given in doses higher than those usually employed clinically. 17 It seems likely that the protective effects against bupivacaine cardio-respiratory toxicity which we have reported for pretreatment with verapamil, 7 and now nicardipine, are due mainly to the antagonism by these agents of the pathophysiological effects of IV bupivacaine. Whether these protective effects are mediated via calcium or sodium channels, both or neither, is uncertain. This desirable property may be common to many, if not all, calcium channel antagonists. Each calcium channel entry blocker would appear to have a different potency in this regard, with the protective potency appearing to parallel the drug's potency for coronary vasodilation. Nicardipine has the most potent protective effect of the agents studied. Nifedipine's potency is greater than that of diltiazem and verapamil, which do not appear to differ greatly from one another.
In addition, calcium channel antagonists reduce cardiac irritability due to elevated catecholamine levels, 18 and this may contribute to their protective effects whenever catecholamine levels are elevated, whether endogenously or exogenously.
We agree with recommendations for the cautious use of calcium channel blockers during general or inhalational anaesthesia. 19 Our results suggest no increased risk of bupivacaine cardio-respiratory toxicity for patients already receiving nicardipine; rather, they suggest a protective benefit from prophylactic or therapeutic use of nicardipine with bupivacaine regional anaesthesia techniques.
In conclusion, our results demonstrate that pretreatment with IV nicardipine, 30 (xg-kg" 1 , reduced the incidence of fatal cardio-respiratory toxicity due to 0.5 per cent bupivacaine, 5 mg-kg" 1 IV, in adult male Sprague Dawley rats. The mechanism of this protective effect is unknown. Whether this protective effect will hold true in humans awaits further study.
